Inve US ▾
CLCLBT

Cellebrite (CLBT) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Information Technology· Aug 13, 2026

Source: earnings call transcript

Executive summary

Cellebrite Q2 FY26 — Leadership Transition Amidst Missed ARR Targets and Strong AI Product Launch

Cellebrite announced a planned CEO transition, appointing Shiven Ramji, amidst a challenging Q2 that saw missed ARR and revenue targets due to deal slippage and lower-than-expected Insights monetization. The company is implementing stricter sales execution and forecasting discipline, while highlighting strong performance in U.S. federal and Defense & Intelligence segments, and promising early adoption of new AI-powered products like Genesis.

Highlights

5
  • Defense and Intelligence ARR grew 25% in Q2 FY26.

  • U.S. federal business had a solid Q2, with growth accelerating into the mid-teens.

  • Genesis, an AI-powered consumption product launched late in Q2, secured $400,000 in ARR in final weeks of June, pushing $1 million ARR post-quarter.

  • Secured first major FedRAMP deal for Guardian, a multi-product multimillion dollar deal with an initial 7-figure order for Guardian alone, 35x higher than average SLG spend.

  • Full-year FY26 adjusted EBITDA target raised to $153 million to $159 million, representing a 28% margin.

Concerns

5
  • Missed Q2 ARR and revenue performance, with ARR increasing 21% to $508 million but below guidance.

  • Full-year FY26 ARR guidance lowered to $550 million to $560 million, a $15 million reduction at the midpoint.

  • Full-year FY26 revenue range reduced to $555 million to $561 million.

  • Slippage in large transactions due to new administrative and procurement requirements related to foreign entity status, particularly with U.S. federal and European government customers, causing approximately 6 weeks of sales cycle elongation.

  • Insights ARR uplift from pricing and footprint expansion was lower than expected, particularly in the U.S. state and local government sector, impacting growth to just below 20%.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 ARR
$550M-$560M
high materiality
High
Full-year 2026 ARR Growth
14%-16%
high materiality
High
Full-year 2026 Revenue
$555M-$561M
high materiality
High
Full-year 2026 Revenue Growth
17%-18%
high materiality
High
Full-year 2026 Adjusted EBITDA
$153M-$159M
high materiality
High
Full-year 2026 Adjusted EBITDA Margin
28%
high materiality
High
Full-year 2026 Free Cash Flow Margin
30%
high materiality
High
Q3 ARR
$524M-$528M
medium materiality
High
Q3 Revenue
$145M-$148M
medium materiality
High
Q3 Adjusted EBITDA
$42M-$45M
medium materiality
High
Q3 Adjusted EBITDA Margin
29%-30%
medium materiality
High
Insights Contribution to Growth
mid-single digits
medium materiality
Medium
Guardian, Pathfinder, Genesis Contribution to Growth
mid-single digits
medium materiality
Medium
Corillium Contribution to Growth
1-2 percentage points
low materiality
Medium
Gross Revenue Retention Rate
at least 1 point improvement
medium materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Americas
U.S. Federal growth accelerated into the mid-teens. U.S. State and Local Government (SLG) growth was just below 20%, down from mid-20s last year, but would have been mid-teens without new offerings.
% of total ARR: 53%
—19%——
EMEA
Experienced slippage in cloud deals due to new EU Freedom of Information requirements, but 4 slipped cloud deals have since closed.
% of total ARR: 34%
—23%——
APAC
Stood out as a strong performer in terms of growth.
% of total ARR: 13%
—29%——
Defense and Intelligence
Outgrowing the rest of the company. Delays are less in this segment compared to civilian federal.
—25%——

Orderbook & backlog

Ending ARR $508M Q2 FY26

up 21% YoY

Annual Recurring Revenue (ARR)

Product announcements

ProductTypeDetails
Genesislaunch
Guardian Investigatemilestone
Advanced Unlocksmilestone
Drone Forensicsmilestone
Shared Cellebrite AI layerroadmap
Carilliumroadmap

Deals & partnerships

U.S. federal customer Multi-product, multi-million dollar FedRAMP deal for Guardian multi-million dollar

First major FedRAMP deal for Guardian with a long-standing U.S. federal customer.

Anchor customer Agreement for Genesis airgap offering

Secured an agreement with an anchor customer for an airgap offering, bringing Genesis capability into high security and on-premise environments.

Risks & headwinds

Slippage in large transactions due to administrative and procurement requirements Q2 FY26, ongoing impact on deal cycles

Caused Q2 ARR and revenue miss; approximately 6 weeks elongation of sales cycles; $4 million of slipped business has since closed.

Mitigation:Implementing stricter sales execution and forecasting discipline; secured a master Foreign Entity Permit (FEP) for U.S. federal cloud technology; improved understanding of EU Freedom of Information requirements for cloud deals.

Lower-than-expected ARR uplift from Insights conversions Q2 FY26, ongoing

Impacted full-year ARR outlook; particularly evident in U.S. state and local government (SLG) sector, where growth is now just below 20% (vs mid-20s last year).

Mitigation:Focusing on new product introductions like Genesis to drive growth and monetization, especially in the SLG sector.

Challenging FX environment FY26

Nearly 3 points of FX headwinds from the ILS impacting the full-year adjusted EBITDA target.

Mitigation:Expect FX headwinds to subside in 2027; continued discipline in managing the business and prioritizing investments.

What to watch in Q3 FY26

Sales execution and forecasting discipline

Next quarter (Q3 FY26) and beyond
Current Missed Q2 ARR and revenue targets due to deal slippage and forecasting issues.
Target Improved execution, earlier risk identification, and greater precision in forecasting.

Why it matters

Directly impacts the company's ability to meet guidance and rebuild investor confidence, especially after the Q2 miss.

We need to execute these opportunities better, identify risks earlier and forecasted business with greater precision.

Find out whether CLBT delivers this. Inve re-checks your case every morning.

Q&A highlights

What gives management confidence in the business's long-term growth potential given the Q2 performance shortfall?

Management expressed confidence based on early positive signals from new products, larger deal sizes, and successful platform orders, including a 5-product platform order for a leading agency. They noted that 4 slipped cloud deals in EMEA have already closed, and they now understand new EU Freedom of Information requirements.

“I mean when you put the quarter in context, we signed and took down orders probably well north of 1,000. In the end, it kind of came down to 4, and it was 4 that across the line, and it was 4 that involve cloud.”

asked by Shaul Eyal · answered by David Barter

2 min read 6 chapters

Detailed narrative

CEO Transition and Strategic Direction

Adam Clammer announced Shiven Ramji as the new CEO, effective immediately, as part of a planned transition accelerated by the need for a product-centric leader focused on scalable, cloud-native platforms and AI. Ramji emphasized compressing the investigative lifecycle and building a broader investigative intelligence platform with a shared Cellebrite AI layer, combining forensic context with evidence-grade controls for provenance, verification, and auditability.

Q2 Performance Shortfall and Sales Execution

The company missed Q2 ARR and revenue expectations, primarily due to large transactions with U.S. federal and European government customers encountering new administrative and procurement requirements related to Cellebrite's foreign entity status. Management is implementing stricter sales execution and forecasting discipline, placing greater weight on observable customer actions and explicitly accounting for large government deals to improve precision.

Insights Monetization Challenges

While customer conversion to Insights reached nearly 65% of the installed base by Q2, the ARR uplift from pricing and footprint expansion was lower than expected, particularly in the U.S. state and local government (SLG) sector. This moderation in incremental price capture at the time of conversion impacted the full-year outlook, with SLG growth now just below 20% compared to mid-20s last year.

Strength in Federal and New Product Adoption

The U.S. federal business had a solid Q2, with Defense and Intelligence ARR growing 25%. New offerings like Guardian Investigate, Advanced Unlocks, and Drone Forensics saw important adoption, with Guardian securing a multi-product, multi-million dollar FedRAMP deal. Genesis, an AI-powered consumption product launched late in Q2, generated $400,000 in ARR in its first weeks and is expanding globally.

Financial Outlook and Profitability

Despite lowering full-year ARR and revenue guidance, Cellebrite raised its full-year adjusted EBITDA target to $153 million to $159 million, reflecting continued discipline and prioritization of investments. The company anticipates delivering 30% free cash flow margins in 2026 and expects a step-up in profitability and FCF in 2027, driven by stable headcount, subsiding FX headwinds, and scaling new products.

Addressing Procurement Delays

Management acknowledged unforeseen procurement challenges, particularly for cloud and AI deals with government agencies, including a 'foreign entity permit' requirement for U.S. federal cloud technology. They have since secured a master FEP and are applying rigorous logic to future deals to prevent similar delays, noting that no deals were lost, and $4 million of slipped business has already closed post-quarter.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.